{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:08:36Z","timestamp":1768205316278,"version":"3.49.0"},"reference-count":43,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T00:00:00Z","timestamp":1756512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the virologic effectiveness and discontinuation of the commonly prescribed fixed\u2010dose combination 3\u2010drug and 2\u2010drug regimens, bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) and dolutegravir\/lamivudine (DTG\/3TC), in virologically suppressed individuals in routine clinical care in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      From the OPERA cohort, ART\u2010experienced, virologically suppressed (viral load &lt;200 copies\/mL) adults with HIV who switched to B\/F\/TAF or DTG\/3TC (01AUG2020\u201030JUN2022) were followed through 31DEC2022, death, loss to follow\u2010up or discontinuation. Cox proportional hazard models with stabilized inverse probability of treatment weights were used to assess the association between regimen and time to confirmed virologic failure (cVF\n                      <jats:sub>200<\/jats:sub>\n                      ; 2 viral loads \u2265200 copies\/mL or 1 viral load \u2265200 copies\/mL\u2009+\u2009discontinuation) or time to discontinuation.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 3512 B\/F\/TAF users were followed for a median of 16\u2009months (IQR: 11, 22); 2327 DTG\/3TC users were followed for a median of 15\u2009months (IQR: 10, 21). cVF\n                      <jats:sub>200<\/jats:sub>\n                      was observed among 2% of B\/F\/TAF and 3% of DTG\/FTC users, for an adjusted hazard ratio of 0.84 (95% CI: 0.59, 1.18) for B\/F\/TAF compared with DTG\/3TC. Regimen discontinuation was observed among 17% of B\/F\/TAF and 19% of DTG\/3TC users, for an adjusted hazard ratio of 0.83 (95% CI: 0.73, 0.94) for B\/F\/TAF compared with DTG\/3TC. Treatment\u2010related reasons for discontinuation represented 6% of B\/F\/TAF and 9% of DTG\/3TC discontinuations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this large US cohort, both B\/F\/TAF and DTG\/3TC were well tolerated and effective treatment options among virologically suppressed individuals in routine clinical care, although DTG\/3TC tended to be discontinued faster than B\/F\/TAF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hiv.70105","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T08:50:03Z","timestamp":1756543803000},"page":"1707-1716","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Suppressed switch to Bictegravir\/emtricitabine\/tenofovir alafenamide compared with dolutegravir\/lamivudine: Real\u2010world evidence from the\n                    <scp>OPERA<\/scp>\n                    cohort"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0159-7243","authenticated-orcid":false,"suffix":"Jr","given":"Gerald","family":"Pierone","sequence":"first","affiliation":[{"name":"Whole Family Health Center  Vero Beach Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-4835","authenticated-orcid":false,"given":"Laurence","family":"Brunet","sequence":"additional","affiliation":[{"name":"Epividian  Raleigh North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1556-811X","authenticated-orcid":false,"given":"Jennifer S.","family":"Fusco","sequence":"additional","affiliation":[{"name":"Epividian  Raleigh North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael G.","family":"Sension","sequence":"additional","affiliation":[{"name":"CAN Community Health  Fort Lauderdale Florida USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9250-5126","authenticated-orcid":false,"given":"Megan S.","family":"Dunbar","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Gruber","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc.  Foster City California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas T.","family":"Dieterich","sequence":"additional","affiliation":[{"name":"Mount Sinai Health System  New York New York USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Fusco","sequence":"additional","affiliation":[{"name":"Epividian  Raleigh North Carolina USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,30]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61809-7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0093-9"},{"key":"e_1_2_10_4_1","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV.2021https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf. (Accessed April 6 2021)."},{"key":"e_1_2_10_5_1","unstructured":"Gilead Sciences.U.S. Food and Drug Administration Approves Gilead's Biktarvy\u00ae (Bictegravir Emtricitabine Tenofovir Alafenamide) for Treatment of HIV\u20101 Infection.2018https:\/\/www.gilead.com\/news\u2010and\u2010press\/press\u2010room\/press\u2010releases\/2018\/2\/us\u2010food\u2010and\u2010drug\u2010administration\u2010approves\u2010gileads\u2010biktarvy\u2010bictegravir\u2010emtricitabine\u2010tenofovir\u2010alafenamide\u2010for\u2010treatment\u2010of\u2010hiv1\u2010infection(accessed Dec 6 2024)."},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32340-1"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32299-7"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30091-2"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(18)30092-4"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01474-16"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02533-18"},{"key":"e_1_2_10_12_1","unstructured":"U.S. Food & Drug Administration (FDA).FDA approves first two\u2010drug complete regimen for HIV\u2010infected patients who have never received antiretroviral treatment \u2010 DovatoFDA News Release2019.https:\/\/www.fda.gov\/news\u2010events\/press\u2010announcements\/fda\u2010approves\u2010first\u2010two\u2010drug\u2010complete\u2010regimen\u2010hiv\u2010infected\u2010patients\u2010who\u2010have\u2010never\u2010received."},{"key":"e_1_2_10_13_1","unstructured":"U.S. Food & Drug Administration (FDA).FDA approved changes to the DOVATO (dolutegravir\/lamivudine) product labeling.https:\/\/www.fda.gov\/drugs\/human\u2010immunodeficiency\u2010virus\u2010hiv\/fda\u2010approved\u2010changes\u2010dovato\u2010dolutegravirlamivudine\u2010product\u2010labeling. (Accessed December 23 2021)."},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300525"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29800"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1243"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa479"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz056"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac130"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002275"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2020.0219"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211034176"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0291480"},{"issue":"1","key":"e_1_2_10_24_1","article-title":"Switching to dolutegravir\/lamivudine or Bictegravir\/emtricitabine\/tenofovir alafenamide. A comparative real\u2010world study. HIV Research & Clinical","volume":"24","author":"Knobel H","year":"2023","journal-title":"Practice"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad338"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00879-x"},{"key":"e_1_2_10_27_1","volume-title":"Non\u2010inferior Efficacy and Less Weight Gain when Switching to DTG\/3TC than when Switching to BIC\/FTC\/TAF in Virologically Suppressed People with HIV (PWH): the PASO\u2010DOBLE (GeSIDA 11720) Randomized Clinical Trial","author":"Ryan P","year":"2024"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-6419.2007.00527.x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3697"},{"key":"e_1_2_10_30_1","volume-title":"Suppressed Switch to DTG\/3TC 2\u2010Drug Regimen Vs. BIC\u2010 or DTG\u2010Based 3\u2010Drug Regimens","author":"Pierone G","year":"2022"},{"key":"e_1_2_10_31_1","volume-title":"Real World Use of Dolutegravir\/Lamivudine in Treatment na\u00efve People Living with HIV during the COVID Pandemic","author":"Pierone G","year":"2022"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-021-00522-7"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13373"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13050"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab481"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/25787489.2021.1965757"},{"key":"e_1_2_10_37_1","first-page":"133","article-title":"Switching to dolutegravir\/lamivudine two\u2010drug regimen: durability and virologic outcomes by age, sex, and race in routine US clinical care","volume":"16","author":"Pierone G","year":"2024","journal-title":"HIV AIDS (Auckl)"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad102"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.12716"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms10020433"},{"key":"e_1_2_10_41_1","unstructured":"Centers for Disease Control and Prevention.HIV Surveillance Report vol. 34: Diagnoses of HIV Infection in the United States and Dependent Areas 2021.2023https:\/\/stacks.cdc.gov\/view\/cdc\/149071(Accessed May 31 2023)."},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz022"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-020-08631-7"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae198"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.70105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:12:28Z","timestamp":1768194748000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.70105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,30]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/hiv.70105"],"URL":"https:\/\/doi.org\/10.1111\/hiv.70105","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,30]]},"assertion":[{"value":"2025-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}